Potential COVID-19 Therapeutic Agents and Vaccines : An Evidence-Based Review
© 2021, The American College of Clinical Pharmacology..
Since the early days of 2020, the severe acute respiratory syndrome coronavirus 2 pandemic has become a global health concern. Currently, some therapies and vaccines have received US Food and Drug Administration approval or emergency use authorization for the management of coronavirus disease 2019. According to the pathophysiology of the disease, several medications have been evaluated in different clinical conditions of the disease. Evidence-based reviewing and categorizing these medications can guide the clinicians to select the proper medications according to each patient's condition. Therefore, we performed this review to categorize the coronavirus disease 2019 potential therapeutics and vaccines.
| Media Type: |
Electronic Article |
|---|
| Year of Publication: |
2021 |
|---|
| Contained In: |
Journal of clinical pharmacology - Vol. 61, No. 4 (2021), p. 429-460 |
|---|
| Language: |
English |
|---|
| Contributors: |
|---|
| Links: |
|---|
| Notes: |
Date Completed 05.04.2021 Date Revised 05.04.2021 published: Print-Electronic Citation Status MEDLINE Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine |
|---|
| Physical Description: |
Online-Ressource |
|---|
| doi: |
10.1002/jcph.1822 |
|---|---|
| PMID: |
33511638 |
| PPN (Catalogue-ID): |
NLM321770625 |
|---|
| LEADER | 04008nma a2200913 c 4500 | ||
|---|---|---|---|
| 001 | NLM321770625 | ||
| 003 | DE-601 | ||
| 005 | 20210406213636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210129s2021 000 0 eng d | ||
| 024 | 7 | |a 10.1002/jcph.1822 |2 doi | |
| 028 | 5 | 2 | |a pubmed21n1222.xml |
| 035 | |a (DE-599)NLM33511638 | ||
| 040 | |b ger |c GBVCP | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Khani, Elnaz | |
| 245 | 1 | 0 | |a Potential COVID-19 Therapeutic Agents and Vaccines |h Elektronische Ressource |b An Evidence-Based Review |
| 300 | |a Online-Ressource | ||
| 500 | |a Date Completed 05.04.2021 | ||
| 500 | |a Date Revised 05.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 500 | |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine | ||
| 520 | |a © 2021, The American College of Clinical Pharmacology. | ||
| 520 | |a Since the early days of 2020, the severe acute respiratory syndrome coronavirus 2 pandemic has become a global health concern. Currently, some therapies and vaccines have received US Food and Drug Administration approval or emergency use authorization for the management of coronavirus disease 2019. According to the pathophysiology of the disease, several medications have been evaluated in different clinical conditions of the disease. Evidence-based reviewing and categorizing these medications can guide the clinicians to select the proper medications according to each patient's condition. Therefore, we performed this review to categorize the coronavirus disease 2019 potential therapeutics and vaccines | ||
| 611 | 2 | 7 | |a Journal Article |2 gnd |
| 611 | 2 | 7 | |a Review |2 gnd |
| 653 | 2 | |a Anti-Inflammatory Agents |6 D000893 |a pharmacology |6 Q000494 |a *therapeutic use |6 Q000627 | |
| 653 | 2 | |a Antibodies, Monoclonal, Humanized |6 D061067 |a pharmacology |6 Q000494 |a *therapeutic use |6 Q000627 | |
| 653 | 2 | |a Antibodies, Neutralizing |6 D057134 |a pharmacology |6 Q000494 |a therapeutic use |6 Q000627 | |
| 653 | 2 | |a Antiviral Agents |6 D000998 |a pharmacology |6 Q000494 |a *therapeutic use |6 Q000627 | |
| 653 | 2 | |a COVID-19 |6 D000086382 |a *drug therapy |6 Q000188 |a immunology |6 Q000276 |a *prevention & control |6 Q000517 | |
| 653 | 2 | |a COVID-19 Vaccines |6 D000086663 |a pharmacology |6 Q000494 |a *therapeutic use |6 Q000627 | |
| 653 | 2 | |a Evidence-Based Medicine |6 D019317 | |
| 653 | 2 | |a Humans |6 D006801 | |
| 653 | 2 | |a Practice Guidelines as Topic |6 D017410 |a standards |6 Q000592 | |
| 653 | 2 | |a SARS-CoV-2 |6 D000086402 |a physiology |6 Q000502 | |
| 655 | 7 | |a COVID-19 |2 gnd | |
| 655 | 7 | |a IFN-β-1a |2 gnd | |
| 655 | 7 | |a SARS-CoV-2 |2 gnd | |
| 655 | 7 | |a baricitinib |2 gnd | |
| 655 | 7 | |a colchicine |2 gnd | |
| 655 | 7 | |a convalescent plasma |2 gnd | |
| 655 | 7 | |a dexamethasone |2 gnd | |
| 655 | 7 | |a methylprednisolone |2 gnd | |
| 655 | 7 | |a remdesivir |2 gnd | |
| 655 | 7 | |a tocilizumab |2 gnd | |
| 655 | 7 | |a Anti-Inflammatory Agents |2 gnd | |
| 655 | 7 | |a Antibodies, Monoclonal, Humanized |2 gnd | |
| 655 | 7 | |a Antibodies, Neutralizing |2 gnd | |
| 655 | 7 | |a Antiviral Agents |2 gnd | |
| 655 | 7 | |a COVID-19 Vaccines |2 gnd | |
| 689 | 0 | 0 | |A f |a Journal Article |
| 689 | 0 | 1 | |A f |a Review |
| 689 | 0 | |5 DE-601 | |
| 689 | 1 | 0 | |a COVID-19 |
| 689 | 1 | 1 | |a IFN-β-1a |
| 689 | 1 | 2 | |a SARS-CoV-2 |
| 689 | 1 | 3 | |a baricitinib |
| 689 | 1 | 4 | |a colchicine |
| 689 | 1 | 5 | |a convalescent plasma |
| 689 | 1 | 6 | |a dexamethasone |
| 689 | 1 | 7 | |a methylprednisolone |
| 689 | 1 | 8 | |a remdesivir |
| 689 | 1 | 9 | |a tocilizumab |
| 689 | 1 | |5 DE-601 | |
| 689 | 2 | 0 | |a Anti-Inflammatory Agents |
| 689 | 2 | 1 | |a Antibodies, Monoclonal, Humanized |
| 689 | 2 | 2 | |a Antibodies, Neutralizing |
| 689 | 2 | 3 | |a Antiviral Agents |
| 689 | 2 | 4 | |a COVID-19 Vaccines |
| 689 | 2 | |5 DE-601 | |
| 700 | 1 | |a Khiali, Sajad | |
| 700 | 1 | |a Entezari-Maleki, Taher | |
| 773 | 0 | 8 | |i in |t Journal of clinical pharmacology |g Vol. 61, No. 4 (2021), p. 429-460 |q 61:4<429-460 |w (DE-601)NLM000005584 |x 1552-4604 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1002/jcph.1822 |3 Volltext |
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2021 |e 4 |b 28 |c 04 |h 429-460 | ||